483
Hagop M. Kantarjian, M.D.FDA 483 - Hagop M. Kantarjian, M.D. - May 05, 2017
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Hagop M. Kantarjian, M.D. in Houston, TX, identified significant deficiencies in the conduct of clinical trials. Observations included the improper documentation of informed consent, where forms were not dated by subjects, and the failure to report adverse experiences to the study sponsor in a timely manner as required by protocol and regulations.
Open in Dashboard
ID · ede3cc71-0ef1-46b5-908a-e128be222fff